Damora Therapeutics, Inc.
Research Damora Therapeutics, Inc. (DMRA) on Bullrun: market cap USD 1.47B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDMRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.47B
- Financial periodQ3 2026
- RevenueUSD 0
- Net income-USD 31.99M
- Free cash flow-USD 17.23M
Valuation Snapshot
latest market cap is USD 1.47B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 209.84M | -USD 6.73M | n/a | -3.98 | USD 257.62M | USD 68.00K | USD 239.04M |
| FY2024 | USD 0 | -USD 21.44M | -USD 18.62M | n/a | -18.53 | USD 14.18M | USD 73.00K | USD 14.47M |
| FY2023 | USD 0 | -USD 38.35M | -USD 36.91M | n/a | -36.08 | USD 21.47M | USD 249.00K | USD 32.33M |
| FY2022 | USD 0 | -USD 61.62M | -USD 43.13M | n/a | -60.75 | USD 32.79M | USD 804.00K | USD 61.75M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 1.47B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 38.14M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.12M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 19.52M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 29.42M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 76.55M | n/a | n/a | n/a |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
ETFs that hold Damora Therapeutics, Inc.
US-listed ETFs
Damora Therapeutics, Inc. is held by 16 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Russell 2000 ETF (IWM) | 0.04% | 0.19% |
| State Street SPDR S&P Biotech ETF (XBI) | 0.17% | 0.35% |
| iShares Russell 2000 Growth ETF (IWO) | 0.06% | 0.24% |
| iShares Russell 2000 Value ETF (IWN) | 0.03% | 0.24% |
| Vanguard Extended Market Index Fund ETF Shares (VXF) | 0.01% | 0.05% |
| iShares Russell 3000 ETF (IWV) | <0.01% | 0.20% |
| Fidelity Nasdaq Composite Index ETF (ONEQ) | <0.01% | 0.21% |
| Fidelity MSCI Health Care Index ETF (FHLC) | 0.02% | 0.08% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Damora Therapeutics, Inc.'s market cap?
Damora Therapeutics, Inc.'s market capitalization is USD 1.47B.
What does Damora Therapeutics, Inc. do?
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.